Cogent Biosciences, Inc. COGT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s financing cash flow?
- Cogent Biosciences, Inc. (COGT) reported financing cash flow of $52.54M in Q1 2026.
- How has Cogent Biosciences, Inc.'s financing cash flow changed year-over-year?
- Cogent Biosciences, Inc.'s financing cash flow increased by 110.4% year-over-year, from $24.97M to $52.54M.
- What is the long-term trend for Cogent Biosciences, Inc.'s financing cash flow?
- Over 3 years (2022 to 2025), Cogent Biosciences, Inc.'s financing cash flow has grown at a 75.1% compound annual growth rate (CAGR), from $163.56M to $878.23M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.